Molekulare Marker zur Diagnostik myeloischer Neoplasien

Genanalysen erlauben die differenzialdiagnostische Zuordnung leukämischer Erkrankungen sowie prädiktive Aussagen zur weiteren Therapieplanung. In diesem Beitrag wird eine Auswahl an myeloischen Entitäten näher beleuchtet und an konkreten Beispielen der Nutzen der neuen molekularen Methoden erläutert.

• Literatur

• 1 Swerdlow SH, Campo E, Harris NL. WHO classification of tumours of haematopoetic and lymphoid tissue (Revised 4th edition). Lyon: IARC; 2017
• 2 Hoffmann VS, Baccarani M, Hasford J. The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries. Leukemia 2015; 29: 1336-1343
• 3 Melo JV. The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood 1996; 88: 2375-2384
• 4 Baccarani M, Deininger MW, Rosti G. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 2013; 122: 872-884
• 5 Elliott MA, Tefferi A. Chronic neutrophilic leukemia: 2018 update on diagnosis, molecular genetics and management. Am J Hematol 2018; 93: 578-587
• 6 Maxson JE, Tyner JW. Genomics of chronic neutrophilic leukemia. Blood 2017; 129: 715-722
• 7 Patnaik MM, Tefferi A. Chronic myelomonocytic leukemia: 2018 update on diagnosis, risk stratification and management. Am J Hematol 2018; 93: 824-840
• 8 Horny HP, Ruck M, Wehrmann M. Blood findings in generalized mastocytosis: evidence of frequent simultaneous occurrence of myeloproliferative disorders. Br J Haematol 1990; 76: 186-193
• 9 Valent P. Mastocytosis: a paradigmatic example of a rare disease with complex biology and pathology. Am J Cancer Res 2013; 3: 159-172
• 10 Cools J, DeAngelo DJ, Gotlib J. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003; 348: 1201-1214